We had 38,777 and 40,277 hits for depression and dementia, respectively, in long-term care facilities or nursing homes. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Research
28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
Dementia-friendly designs are important in residential care homes but an aspect that remains neglected is the potential role of door designs in promoting wayfinding. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
The purpose of this study was to use routinely collected resident assessment data from a single site to evaluate the impact of COVID-19 restrictions on cognition, physical function and behavioral symptoms of residents with dementia. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
41/100
It is estimated that 5.4 million Americans have some form of dementia and these numbers are expected to rise in the coming decades, leading to an unprecedented demand for memory care housing and services. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
41/100
Dementia is a progressive, irreversible illness and leading global cause of death defined by cognitive and subsequent functional decline. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Advance care planning (ACP) is an essential element of neuropalliative care for persons living acquired brain injuries or progressive, neurodegenerative conditions like dementia. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Dementia is a terminal illness that leads to progressive cognitive and functional decline. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Care of the dementia patient continues to be challenging. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Palliative care including hospice care is appropriate for advanced dementia, but policy initiatives and implementation have lagged, while treatment may vary. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
41/100
At time of death, the majority of decedents with dementia had advance directives, health care agents, and previous goals of care conversations with their caregiver. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Dementia is a progressive, incurable condition that causes limitations in life and should be recognized as a life-limiting condition. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
While advance care planning (ACP) can help elicit preferences and is associated with improved end-of-life outcomes, persons living with dementia (PLWD) in nursing homes are rarely included in ACP. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
41/100
Dysphagia is recognised as part of the frailty syndrome, especially for those at the end of life. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Although neuropalliative care is a relatively new field, there is increasing evidence for its use among the degenerative parkinsonian syndromes, including idiopathic Parkinson disease, progressive supranuclear palsy, multiple system atrophy, dementia with Lewy bodies, and corticobasal syndrome. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
With the geriatric population in the United States growing rapidly, the prevalence of dementia is expected to rise concomitantly. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
41/100
We found dilemmas regarding palliative care to be the main theme, including definition of the disease as terminal, choosing "comfort" over "life-prolonging," clarifying patients' wishes and deciding whether or not to use artificial feeding. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Older people with dementia have multiple palliative care needs, with pain, agitation, dyspnoea, aspiration and pressure ulcers being common and persistent in advanced dementia. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
High management support aligned with implementation effectiveness within NHs. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
ACP documentation >30 days before death was associated with lower odds of in-hospital death for all 4 conditions both in patients with and without multimorbidity. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Patients in Group 1 were on statistically significant fewer medications than Group 2 at both week 4 and weeks 7-12 following admission. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Lewy body dementia (LBD) is asynucleinopathy that results in clinical manifestation of motor and neuropsychiatric symptoms. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Discrete-time hazard regression results show that sibling loss in mid-to-late life is associated with up to 54% higher risk for dementia. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
White respondents lived a greater percentage of their remaining lives cognitively healthy than their minority Black or Hispanic counterparts, regardless of level of education. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD) and Alzheimer's Disease-Related Dementias (ADRD) are chronic illnesses that are highly prevalent in African Americans (AA). 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD) and vascular dementia are two of the most prevalent dementias that afflict the aging population in the United States (US). 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →